Duality Advisers LP acquired a new position in Vericel Co. (NASDAQ:VCEL – Get Rating) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 8,642 shares of the biotechnology company’s stock, valued at approximately $228,000.
Several other institutional investors also recently bought and sold shares of VCEL. BlackRock Inc. lifted its position in Vericel by 1.3% during the third quarter. BlackRock Inc. now owns 7,180,238 shares of the biotechnology company’s stock valued at $166,583,000 after purchasing an additional 92,494 shares during the last quarter. State Street Corp lifted its position in Vericel by 15.6% during the second quarter. State Street Corp now owns 3,400,735 shares of the biotechnology company’s stock valued at $85,631,000 after purchasing an additional 458,219 shares during the last quarter. Vanguard Group Inc. lifted its position in Vericel by 2.8% during the third quarter. Vanguard Group Inc. now owns 3,234,095 shares of the biotechnology company’s stock valued at $75,031,000 after purchasing an additional 88,923 shares during the last quarter. Conestoga Capital Advisors LLC lifted its holdings in shares of Vericel by 53.6% in the 4th quarter. Conestoga Capital Advisors LLC now owns 2,346,776 shares of the biotechnology company’s stock worth $61,814,000 after acquiring an additional 818,455 shares during the last quarter. Finally, Fred Alger Management LLC lifted its holdings in shares of Vericel by 0.5% in the 3rd quarter. Fred Alger Management LLC now owns 1,944,578 shares of the biotechnology company’s stock worth $45,114,000 after acquiring an additional 10,557 shares during the last quarter.
Wall Street Analyst Weigh In
Several equities research analysts have recently issued reports on the stock. StockNews.com assumed coverage on shares of Vericel in a report on Thursday, March 16th. They issued a “hold” rating for the company. HC Wainwright restated a “buy” rating and issued a $37.00 target price on shares of Vericel in a report on Friday, January 27th. Finally, Truist Financial lifted their price objective on shares of Vericel from $29.00 to $31.00 and gave the company a “hold” rating in a report on Monday, February 27th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, Vericel presently has an average rating of “Hold” and an average target price of $35.50.
Vericel Price Performance
Vericel (NASDAQ:VCEL – Get Rating) last announced its quarterly earnings results on Thursday, February 23rd. The biotechnology company reported $0.12 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.10. Vericel had a negative net margin of 10.17% and a negative return on equity of 9.32%. The firm had revenue of $52.70 million during the quarter, compared to analysts’ expectations of $52.95 million. During the same quarter in the prior year, the company earned $0.09 EPS. The company’s revenue was up 10.7% compared to the same quarter last year. On average, equities analysts anticipate that Vericel Co. will post -0.26 earnings per share for the current fiscal year.
About Vericel
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient’s own knee.
Featured Articles
- Get a free copy of the StockNews.com research report on Vericel (VCEL)
- Is the Electric Vehicle Movement Losing Steam?
- 3 High-Yield Banks Insiders Are BuyingÂ
- Will ChatGPT Be the Final Nail in the Coffin for Chegg?
- Is the Market Reacting Too Negatively to Pinterest Earnings?
- More Analysts Should See Energizer Holdings As A Buy: Here Is Why
Want to see what other hedge funds are holding VCEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vericel Co. (NASDAQ:VCEL – Get Rating).
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.
